{"entity":{"id":"nct00434148","kind":"trial","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","aka":[],"tldr":"A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","summary":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease is a phase 3 interventional study registered as NCT00434148 by Novartis Pharmaceuticals, with 162 participants recorded, started 2006-12 and reaching its primary completion in 2010-03. Interventions recorded: Pasireotide. Conditions recorded: Cushing's Disease.\n\nLinked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00434148","url":"https://clinicaltrials.gov/study/NCT00434148"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["pasireotide"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00434148","phase":"3","setting":"A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT00434148","source":"https://clinicaltrials.gov/study/NCT00434148","fetchedAt":"2026-10-07T16:52:04.776Z","studySha256":"2b069eb9892ed1af6fcfd7783e9e81cfc2ced1dcd8fc72f69d34a5e3fce3c5ab","overallStatus":"COMPLETED","lastUpdatePosted":"2016-03-08","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":162,"enrolmentType":"ACTUAL","siteCount":68,"recruitingSiteCount":0,"countries":["Argentina","Belgium","Brazil","Canada","China","Denmark","Finland","France","Germany","Greece","Israel","Italy","Mexico","Poland","Portugal","Spain","Turkey (Türkiye)","United States"]}],"started":"2006-12","yearReported":2013,"enrolled":162,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group","primary":true,"unit":"participants","arms":[{"name":"Pasireotide 600 ug","n":82,"value":12,"note":"95% CI 7.0 to 22.3; Figures from the ClinicalTrials.gov results section (first posted 2013-02-06), not from a publication"},{"name":"Pasireotide 900 ug","n":80,"value":21,"note":"95% CI 16.6 to 35.9"}],"source":"https://clinicaltrials.gov/study/NCT00434148?tab=results"}]},"route":"/trials/nct00434148/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}